Fig. 4: Neutralization activity of convalescent and vaccine-elicited sera against possible Delta variants with multiple amino acid changes in RBD. | Signal Transduction and Targeted Therapy

Fig. 4: Neutralization activity of convalescent and vaccine-elicited sera against possible Delta variants with multiple amino acid changes in RBD.

From: The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain

Fig. 4: Neutralization activity of convalescent and vaccine-elicited sera against possible Delta variants with multiple amino acid changes in RBD.

The neutralization activity of convalescent serum (a), recombinant S protein vaccine-immunized sera (b and c), and inactive vaccine-immunized sera (d) against different potential SARS-CoV-2 variants were tested. Mean ED50 from three repeated experiments are shown as dot plots. The dashed lines represent the geometric mean and fourfold reduction for serum response of the reference Delta variant, respectively. RBD receptor binding domain, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, ED50 50% effective dilution

Back to article page